Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,194.93 +14.19 (+0.27%) Dow
38,942.31 +90.04 (+0.23%) Nasdaq
16,380.76 +31.51 (+0.19%) Bitcoin USD
63,902.21 +618.77 (+0.98%) CMC Crypto 200
1,329.14 -35.99 (-2.64%)
Xeris Biopharma Holdings, Inc. (XERS)
| Previous close | 1.8950 |
| Open | 1.9100 |
| Bid | 1.8700 x 800 |
| Ask | 1.9200 x 800 |
| Day's range | 1.8400 - 1.9300 |
| 52-week range | 1.4600 - 3.2600 |
| Volume | |
| Avg. volume | 1,875,814 |
| Market cap | 280.941M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
CHICAGO, May 06, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-h
- Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
CHICAGO, May 02, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Comp
- Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.
